US2016279127A1PendingUtilityA1
Heteroaryl compounds and uses thereof
Est. expiryOct 19, 2027(~1.3 yrs left)· nominal 20-yr term from priority
A61P 5/00A61P 43/00A61P 9/10A61P 35/00A61P 3/10A61P 35/04A61P 35/02A61P 37/06A61P 37/00A61P 29/00A61P 25/00A61P 11/00A61P 21/04A61P 1/04A61P 19/10A61P 19/00A61P 19/02A61P 17/00C07D 413/12A61K 31/505C07D 403/12C07D 401/12A61K 31/5377A61K 31/506A61K 45/06C07D 495/04C07D 239/48C07D 487/04Y02P20/582C07D 239/47A61K 31/495C07D 239/32
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Claims
exact text as granted — not AI-modified1 - 2 . (canceled)
3 . A combination comprising:
(i) a composition comprising a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle, and
(ii) an additional therapeutic agent.
4 . The combination according to claim 3 , wherein the additional therapeutic agent is a chemotherapeutic agent.
5 - 39 . (canceled)
40 . The combination according to claim 3 , wherein the composition and the additional therapeutic agent are combined in a single unit dosage form.
41 . The combination according to claim 3 , wherein the composition and the additional therapeutic agent are in separate unit dosage forms.
42 . The combination according to claim 40 , wherein the additional therapeutic agent is a chemotherapeutic agent.
43 . The combination according to claim 41 , wherein the additional therapeutic agent is a chemotherapeutic agent.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.